App-Quantinova.ai

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110/p110 and HDAC6 with single-agent and combination activity

Stephen J. Shuttleworth - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of PD-L1 expression in patients with metastatic GEP-NETs

Seung T. Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A DNA damage response deficiency (DDRD) group in breast cancer is associated with activation of the STING innate immune pathway and PD-L1 expression

Eileen E. Parkes - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy

Rishil J. Kathawala - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398

Jodi A. McKenzie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

Metformin reduces intratumoral CD8+PD-1+ and Treg lymphocytes in orthotopic models of breast cancer and lymphoma, and has paradoxic effects on anti-PD-L1 treatment

Stefania Orecchioni - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Metformin Hydrochloride

Development of a successful combination therapy for hepatocellular cancer by targeting Treg and PD-1

Dai Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A novel immunotherapy, INT230-6, is able to induce high rates of complete response in mice through a cytotoxic T-cell-dependent mechanism

Ian B. Walters - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vinblastine

The expression of PD-L1 on human and murine pancreatic ductal adenocarcinoma is enhanced by anticancer agents via the JAK/STAT pathway

Toshifumi Doi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of novel targeted and immunotherapy combinations by a high throughput assay of T cell-mediated cytotoxicity

Leila Williams - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ipilimumab

Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy

Maria E. Rodriguez-Ruiz - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands

Maria E. Rodriguez-Ruiz - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Personalizing the synergy of focal radiation and immunotherapy

Jan Poleszczuk - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Inhibiting DNA methylation causes an interferon response in cancer cells via endogenous retroviruses and recruits immune cells to the tumor microenvironment to sensitize to immune therapy

Katherine B. Chiappinelli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

5-Azacytidine

Inhibition of KIT in vivo modifies immune cell populations to improve the efficacy of checkpoint inhibitors in syngeneic mouse tumor models

Andrew J. Garton - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma

Marius Ilie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Epigenetic changes in T cells in response to immune checkpoint blockade

Sangeeta Goswami - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

Recurrent gains of CD274 (PD-L1) and PDCD1LG2 (PD-L2) provide a genetic basis for PD-1 ligand expression in a subset of solid tumors

Evisa Gjini - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Modulation of tumor PD-L1 expression by epithelial-mesenchymal phenotypic plasticity

Justin M. David - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adenosine regulates radiation therapy-induced antitumor immunity

Erik Wennerberg - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Adenosine

Filters

41730 Abstracts